Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170456
Status:
COMPLETED
Last Update Posted:
2008-09-15
First Post:
2005-09-09
Brief Title:
Phase II Study of Range and Schedule of rPA Doses
Sponsor:
PharmAthene UK Limited
Organization:
PharmAthene UK Limited
Study Overview
Official Title:
A Double-Blind Parallel-Group Study of the Safety Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant rPA Based Anthrax Vaccine in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a dose ranging study comparing different vaccine schedules of rPA vaccine for anthrax Safety and the capability to induce an immune response will be evaluated
Detailed Description:
Anthrax is a zoonotic disease occurring in wild and domestic mammals caused by the spore forming bacterium Bacillus anthracis Anthrax occurs in humans when they are exposed to infected animals tissue from infected animals or when they are directly exposed to B anthracis or its spores In the USA the annual incidence of human anthrax has declined However in the USA shortly after September 11th 2001 there were 22 cases 18 confirmed of inhaled and cutaneous anthrax infections that were related to contaminated mail This is a double blind parallel-group dose ranging study of rPA anthrax vaccine The subjects will be blinded as to which dose of rPA vaccine is administered The primary objectives of this clinical trial are 1 To evaluate the safety and tolerability associated with different primary immunization doses and schedules of rPA vaccine to enable determination of the optimum dose for future clinical trials and 2 To evaluate the immunogenicity of different primary immunization doses and schedules of rPA vaccine to enable determination of the optimum schedule for future clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| QGUY2004AV-rPA-01 | None | None | None |